# Biogen to pay up to $850 million to acquire exclusive rights in Greater China to an experimental immune disease treatment.

*biotech · news · 2026-04-20 · MarketScreener*

## Key points

- Biogen will pay TJ Biopharma up to $850 million for Greater China rights to felzartamab.
- The agreement grants Biogen worldwide rights to develop and market felzartamab.
- Biogen will assume all milestone and royalty obligations previously owed to MorphoSys by HI-Bio.
- Felzartamab is under review in China for multiple myeloma and in late-stage trials for kidney diseases.

**Companies:** Biogen, TJ Biopharma
**Countries:** United States, China

[Read the full story on MarketScreener](https://www.marketscreener.com/news/biogen-buys-china-rights-to-immune-disease-drug-in-up-to-850-million-deal-with-tj-biopharma-ce7f59dad980ff24)

---

Canonical: https://newsio.io/n/0d936a84-32e5-444a-a57e-2abf3600a50b/biogen-to-pay-up-to-850-million-to-acquire-exclusive-rights-in-greater-china-to
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works